Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 (‘casein kinase-2’)  by Sarno, Stefania et al.
Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed
inhibitor of protein kinase CK2 (‘casein kinase-2’)
Stefania Sarnoa;1, Helen Reddyb;1, Flavio Meggioa, Maria Ruzzenea, Stephen P. Daviesb,
Arianna Donella-Deanaa, David Shugarc, Lorenzo A. Pinnaa;*
aDepartment of Biological Chemistry, University of Padua, and CNR Biomembrane Research Center, viale G. Colombo 3, 35121 Padua, Italy
bDivision of Signal Transduction Therapy, University of Dundee, Dundee DD1 5EH, UK
cInstitute of Biochemistry and Biophysics, Polish Academy of Sciences, 5A Pawinskiego St., 02-106 Warsaw, Poland
Received 30 January 2001; revised 5 April 2001; accepted 6 April 2001
First published online 20 April 2001
Edited by Giulio Superti-Furga
Abstract The specificity of 4,5,6,7-tetrabromo-2-azabenzimi-
dazole (TBB), an ATP/GTP competitive inhibitor of protein
kinase casein kinase-2 (CK2), has been examined against a panel
of 33 protein kinases, either Ser/Thr- or Tyr-specific. In the
presence of 10 WM TBB (and 100 WM ATP) only CK2 was
drastically inhibited (s 85%) whereas three kinases (phosphor-
ylase kinase, glycogen synthase kinase 3L and cyclin-dependent
kinase 2/cyclin A) underwent moderate inhibition, with IC50
values one^two orders of magnitude higher than CK2 (IC50 = 0.9
WM). TBB also inhibits endogenous CK2 in cultured Jurkat cells.
A CK2 mutant in which Val66 has been replaced by alanine is
much less susceptible to inhibition by TBB as well as by another
ATP competitive inhibitor, emodin. These data show that TBB is
a quite selective inhibitor of CK2, that can be used in cell-based
assays. ß 2001 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
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1. Introduction
Protein kinases make up one of the largest family of en-
zymes, being committed to the catalysis of protein phosphor-
ylation, which is the most general and frequent mechanism
controlling diverse aspects of cell life. About one third of
mammalian proteins contain covalently bound phosphate
and there are likely to be about 1000 protein kinases encoded
by the human genome, considering that in the eukaryotic
organism Caenorhabditis elegans 2.5% of the genome encodes
protein kinases [1]. Given these premises, it is not surprising
that protein kinases play a key role in nearly all signal trans-
duction pathways and that altered functions of individual
protein kinases underlie numerous pathological conditions,
including those due to uncontrolled cell proliferation. Perti-
nent to this is the observation that more than half of the
proto-oncogenes encode protein kinases, the others being ei-
ther targets or regulators (or both) of protein kinases. A ma-
jor challenge in this ¢eld is therefore to develop highly selec-
tive inhibitors of individual protein kinases: these may prove
useful for identifying the physiological targets and precise
cellular functions of these enzymes and they may give rise
to new therapeutic agents applicable in many di¡erent disease
indications [2,3]. Despite their wide di¡erences in substrate
speci¢city and regulatory mechanism Mg-ATP is a common
substrate to all eukaryotic protein kinases, whose ATP bind-
ing site consequently is highly conserved [4]. Initially, there-
fore, the design of ATP site-directed inhibitors was considered
unlikely to result in selectivity, due to the assumption that the
ATP binding site is almost identical among protein kinases.
However empirical observations that some quite speci¢c in-
hibitors of protein kinases, currently in the early phases of
clinical trials (e.g. [5^7]), are competitive with respect to
ATP, in conjunction with the solution of crystal structures
of protein kinases in complex with inhibitors (e.g. [8^10]),
have shown that such a priori concerns were unfounded.
The structural rationale for the speci¢city of inhibitors com-
petitive with respect to ATP is provided by a number of
variable and sometimes quite unique features surrounding
the otherwise conserved ATP binding site [11]. These provide
speci¢c pockets and/or docking sites where the inhibitor binds
thereby interfering with the correct binding of ATP [9,10,12].
The most pleiotropic protein kinase known is probably
CK2, an acronym derived from the misnomer ‘casein ki-
nase-2’ used for a long time to indicate a ubiquitous Ser/
Thr-speci¢c, acidophilic kinase tested routinely in vitro on
casein. CK2 is, however, unrelated physiologically to casein,
while it phosphorylates a plethora of cellular proteins (more
than 200 are currently known) sharing with casein the con-
sensus sequence S/T-x-x-E/D/Sp/Yp [13^15]. Recently it has
been shown that CK2 can also phosphorylate tyrosyl residues
[16^18] albeit less e⁄ciently than Ser/Thr ones. The CK2 ho-
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loenzyme is a tetramer composed of two catalytic (K and/or
KP) and two ‘regulatory’ L subunits. The crystal structure of
maize CK2K subunit (70% identical to its human homologue)
has been solved either alone [19] or in complex with a frag-
ment of the human L subunit, to give a tetramer that may
provide some features of the whole holoenzyme [20]. The lat-
ter has been crystallized [21] but its structure is not yet avail-
able.
High constitutive activity is suspected to underlie the patho-
genic potential of CK2, which is exploited by several viruses
to perform the phosphorylation of proteins essential to their
life cycle (reviewed in [22]), and whose catalytic subunits co-
operate with other proto-oncogenes to promote cell transfor-
mation in di¡erent experimental models [23^26]. This makes
CK2 an attractive target in the search for new antineoplastic
and antiviral agents. In addition, the availability of small, cell-
permeable inhibitors of CK2 could be used to implicate this
pleiotropic enzyme in di¡erent cellular functions and path-
ways. Among the compounds which have been reported to
inhibit CK2 in a relatively selective manner are emodin [27]
and a halogenated derivative of benzotriazole, 4,5,6,7-tetra-
bromo-2-azabenzimidazole (TBB) [28]. The latter belongs to
a class of compounds related to commercially available 1-(L-
D-ribofuranosyl)-5,6-dichlorobenzimidazole (DRB), which is
marketed as a CK2 inhibitor. Emodin (3-methyl-1,6,8-trihy-
droxyanthraquinone), however, is also used widely as an in-
hibitor of receptor tyrosine kinases [29,30] and DRB, which
has been tested only on a small number of protein kinases,
inhibits the other class of ubiquitous CKs (CK1) almost as
e⁄ciently as CK2 [31]. By contrast, TBB discriminates be-
tween CK2 and CK1, being much more e¡ective with the
former [28,32]. However a systematic analysis of the inhibi-
tory power of TBB toward a wide spectrum of protein kinases
was lacking. This gap has been ¢lled now by testing the in-
hibitory power of TBB on a panel of 33 protein kinases,
which includes the classical second messenger-dependent pro-
tein kinases implicated in signaling pathways, all the di¡erent
types of CKs and a number of protein tyrosine kinases. Our
data disclose a remarkable selectivity of TBB toward CK2
since no other kinase is inhibited with comparable e⁄ciency.
They also provide evidence that TBB can be used to inhibit
CK2 in cultured cells and show that the replacement of a
conserved Ala present in nearly all the other kinases by a
more hydrophobic residue (Val66 in human CK2) is an im-
portant feature in conferring inhibitability by this compound.
2. Materials and methods
2.1. Materials
Histone H1 was purchased from Life Technologies (Paisley, UK).
Synthetic peptides RRRADDSDDDDD, RRKDLHDDEEDEAMSI-
TA and KKIEKFQSEEQQQ were kindly provided by Dr. O. Marin
(Padova, Italy). Synthesis of TBB was performed as in [28].
2.2. Source and puri¢cation of protein kinases
Native CK1 (nCK1) and nCK2 were puri¢ed from rat liver [33];
Golgi CK (G-CK), puri¢ed from rat lactating mammary gland [34],
was a gift of Dr. A.M. Brunati (Padova, Italy); protein tyrosine ki-
nases Lyn [35], c-Fgr [36], Syk (also termed TPK-IIB) and C-terminal
Src kinase (CSK) [37] were puri¢ed from rat spleen. Human recombi-
nant K and L subunits of CK2 were expressed in Escherichia coli and
the holoenzyme was reconstituted and puri¢ed as described in [38].
The generation, expression and puri¢cation of the V66A mutant of
CK2K subunit are described in [39]. Saccharomyces cerevisiae piD261
and Xenopus laevis CK1K, kindly provided by Dr. S. Facchin (Pado-
va, Italy) and by Dr. V. Pulgar (Santiago, Chile), respectively, were
expressed as His-tagged recombinant proteins in E. coli and puri¢ed
as described in [40,41]. Cyclin-dependent kinase (CDK) 2/cyclin A
(human) and CDK1/cyclin B (star¢sh) were a generous gift from
Dr. J. Endicott (Oxford University, Oxford, UK) and Dr. L. Meijer
(Rosco¡, France), respectively. The source of all the other protein
kinases is either described or referenced in [42].
2.3. Protein kinase assays
All protein kinase activities were linear with respect to time in every
incubation. Assays were performed as detailed in [42] for all kinases
except CK2, CK1 and G-CK which were tested on their speci¢c pep-
tide substrates, RRRADDSDDDDD, RRKDLHDDEEDEAMSITA
[43] and KKIEKFQSEEQQQ [44], respectively, piD261, tested on
casein [40], and tyrosine kinases Lyn, c-Fgr, Syk and CSK whose
assays were performed using angiotensin II as substrate [35]. CDK2/
cyclin A was assayed using histone H1 as substrate. The assays were
carried out in a ¢nal volume of 25 Wl containing 50 mM HEPES pH
7.5, 1 mM dithiothreitol, 0.02% Brij 35, 100 mM NaCl, 1 mg/ml
histone H1, 10 mM magnesium acetate and 0.1 mM [Q-33P]ATP
(500^1000 cpm/pmol) and incubated for 40 min at room temperature.
These conditions are suited for reaching maximal velocity with all
protein kinases. Assays were stopped by addition of 5 Wl of 0.5 M
orthophosphoric acid before spotting aliquots onto P30 ¢ltermats
(Wallac). Filtermats were washed in 75 mM phosphoric acid (5^10
ml/each ¢ltermat) four times then once in methanol and dried before
counting.
2.4. Cell culturing, treatment and lysis
The human leukemia Jurkat T-cell line was maintained in RPMI
1640 supplemented with 10% fetal calf serum, 10 mM HEPES, 2 mM
L-glutamine, 100 U/ml penicillin, and 100 Wg/ml streptomycin.
Cell treatment was performed by incubation of cell suspension
(V10U106 cells/ml) for 2 h at 37‡C in the presence of 2 WM okadaic
acid (OA) with the addition of protein kinase inhibitors where indi-
cated. After incubations, cells were centrifuged and lysed for 15 min in
ice-cold bu¡er consisting of 20 mM Tris^HCl pH 7.4, 2 mM EDTA,
2 mM EGTA, 10 mM 2-mercaptoethanol, 10% (v/v) glycerol, 1 mM
Na3VO4, 0.05% Nonidet P-40, protease inhibitor cocktail (Boehr-
inger), 10 mM NaF, 1 WM OA. The lysate was cleared by centrifuga-
tion for 10 min at 14 000 rpm (Eppendorf Microfuge 5415C).
2.5. Immunoprecipitation and immunoblotting
The lysate corresponding to V5U106 cells was used for HS1 (hem-
atopoietic lineage cell-speci¢c protein 1) immunoprecipitation, per-
formed by incubation at 4‡C for 2 h with 2.5 Wl of anti-HS1 antiserum
[45], followed by addition of protein A-Sepharose. Immunoprecipi-
tates were washed twice with NET bu¡er (50 mM Tris^HCl pH 8.0,
150 mM NaCl, 5 mM EDTA, 0.05% (v/v) Nonidet P-40, 2 mg/ml
bovine serum albumin) and once with 50 mM Tris^HCl pH 7.5,
boiled for 3 min and loaded onto 10% SDS^PAGE. Gels were trans-
blotted to Immobilon-P membranes (Millipore) and analyzed by
Western blot with the same anti-HS1 antiserum. Development was
performed with an enhanced chemiluminescence detection system
(Amersham Pharmacia). In the case of phosphatase treatment, before
boiling, pellets from immunoprecipitation were incubated for 2 h at
30‡C with acidic phosphatase from potato (3 Wg) (Boehringer Mann-
heim) in the presence of 100 mM acetate bu¡er, pH 5.5.
3. Results
In Table 1 the activity of 33 protein kinases, assayed at 100
WM ATP in the presence of 10 WM TBB, is expressed relative
to that measured in the absence of the inhibitor. Only with
CK2 inhibition is s 85%. A signi¢cant, albeit much less pro-
nounced inhibition is also observed with three Ser/Thr protein
kinases, besides CK2, namely CDK2/cyclin A (30%), phos-
phorylase kinase (PHK) (51%) and glycogen synthase kinase
3L (GSK3L) (36%). With the remaining 29 protein kinases
(including all the tyrosine protein kinases tested) no appreci-
able inhibition was observed.
The IC50 values for TBB were determined with CK2 and
FEBS 24832 1-5-01
S. Sarno et al./FEBS Letters 496 (2001) 44^48 45
the other three kinases a¡ected signi¢cantly by 10 WM TBB.
As shown in Table 2, the IC50 values with CDK2, PHK and
GSK3L are one^two orders of magnitude higher than those
calculated with either nCK2 or recombinant CK2 (rCK2).
The Ki values for TBB of CK2 and CK1 were found to be
0.4 and 47 WM, respectively. Similar results were obtained if
CK2 activity was monitored using the tyrosyl peptide sub-
strate DEADIYDEEDYDL [17] instead of the usual seryl
one (not shown).
Next we wanted to check whether TBB also inhibits CK2 in
intact cells. For this purpose, we took advantage of the be-
havior of HS1 which upon Ser/Thr phosphorylation by CK2
undergoes a shift on SDS^PAGE not observed when the same
protein is tyrosine-phosphorylated by Syk and Src family pro-
tein kinases [45]. As shown in Fig. 1A, HS1 immunoprecipi-
tated from Jurkat cells treated with OA undergoes an upward
shift similar to that observed in vitro upon phosphorylation
by CK2 (Fig. 1B). The up-shift of the HS1 immunodetected
band is counteracted by treatment of Jurkat cells with 60 WM
TBB (compare lanes 3 and 1). The same is observed if the cells
are treated with emodin, another inhibitor of CK2 [12,27]
albeit less selective than TBB, while 0.1 WM staurosporine, a
broad speci¢city inhibitor of protein kinases, does not prevent
the up-shift of the HS1 band. Unlike most protein kinases,
which are inhibited by staurosporine with IC50 values in the
low nanomolar range [46,47], CK2 is unusually resistant to
staurosporine, with a IC50 of about 19.5 WM [48]. These data
corroborate the concept that CK2 is responsible for the up-
Table 2
TBB concentration required for 50% inhibition of TBB sensitive
protein kinases
Protein kinase IC50 (mM) þ S.D.
nCK2 (rat liver) 0.9 þ 0.4
rCK2 (human) 1.6 þ 0.3
nCK1 (rat liver) 83.0 þ 2.5
rCK1K (X. laevis) 80.1 þ 1.9
CDK1/cyclin B s 100.0
CDK2/cyclin A 15.6 þ 2.1
GSK3L 11.2 þ 1.6
PHK 8.7 þ 0.7
The ATP concentration was 100 WM in all assays. Phosphorylation
conditions are described under Section 2.
Table 1
Susceptibility of protein kinases to 10 mM TBB
Protein kinase Activity (10 WM TBB) S.D.
MKK1 94 1
MAPK2/ERK2 111 4
JNK1/SAPK1c 93 4
SAPK2a/p38 107 1
SAPK2b/p38b2 103 1
SAPK3/p38g 89 2
SAPK4/p38d 99 2
MAPKAP-K1b 90 7
MAPKAP-K2 108 2
MSK1 111 5
PRAK 87 1
PKA 90 2
PKCK 102 1
PDK1 97 1
PKBK 91 3
SGK 97 6
p70S6K 89 4
GSK3L 64 1
ROCK-II 91 3
AMPK 96 1
CHK1 101 1
PHK 49 1
CDK1/cyclin B 102 3
CDK2/cyclin A 70 5
CK2 13 1
CK1 91 1
G-CK 95 4
piD261 98 2
Lck 98 4
Lyn 99 1
c-Fgr 98 1
Syk 102 2
CSK 101 3
Activity is expressed as a percentage of controls without TBB (in
the presence of DMSO alone). ATP was always 100 WM. Source of
protein kinases and assay conditions are described in Section 2.
MAPK, mitogen-activated protein kinase; MKK, MAPK kinase
(also called MEK); ERK, extracellular signal-regulated kinase;
JNK, c-Jun N-terminal kinase; SAPK, stress-activated protein ki-
nase; MAPKAP, MAPK-activated protein kinase; MSK, mitogen-
and stress-activated protein kinase; PRAK, p38-regulated/activated
kinase; PKA, cAMP-dependent protein kinase; PKC, protein kinase
C; PDK, 3-phosphoinositide-dependent kinase; PKB, protein kinase
B (also called Akt); SGK, serum- and glucocorticoid-induced ki-
nase; p70S6K, p70 ribosomal protein S6 kinase; ROCK, Rho-de-
pendent protein kinase; AMPK, AMP-activated protein kinase;
CHK, checkpoint kinase; CDK, cyclin-dependent kinase.
Fig. 1. TBB inhibits CK2-mediated HS1 phosphorylation in Jurkat cells. (A) HS1 was immunoprecipitated from Jurkat cells treated for 2 h
with 2 WM OA and the indicated protein kinase inhibitors at the following concentrations: staurosporine, 0.1 WM; TBB, 60 WM; emodin, 60
WM. Samples of lanes 5 and 6 were treated with acidic phosphatase, after HS1 immunoprecipitation, as described under Section 2. (B) Re-
combinant His-tagged HS1 was analyzed directly (lane 7) or after in vitro phosphorylation by CK2, as described in [41] (lanes 8 and 9). In the
case of lane 9, the phosphorylation reaction was followed by thermal inactivation of CK2 and incubation with acidic phosphatase. Analyses
were performed by SDS^PAGE and Western blot with anti-HS1 antibodies. The arrows denote the positions of unphosphorylated HS1 (A)
and recombinant HS1 expressed with a His tag (B), respectively. The up-shifted immunoreactive band detectable both in vivo (A) and in vitro
(B) is due to phosphorylated HS1 as it disappears upon treatment with acidic phosphatase.
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shift of HS1. That indeed such an up-shift is due to HS1
phosphorylation was con¢rmed by showing that it was re-
versed if the immunoprecipitates were treated with acidic
phosphatase (see Fig. 1A, lane 5), a treatment that also re-
verses the HS1 up-shift induced by incubating recombinant
HS1 with CK2 in vitro (Fig. 1B).
Modelling studies suggested that TBB is accommodated
into a hydrophobic pocket generated by several non-polar
residues [48]. One of these, Val66, attracted our attention
for two reasons: ¢rstly this valine is unique to CK2, being
replaced by an alanine in nearly all the other protein kinases;
secondly this valine is replaced conservatively by isoleucine in
maize CK2K (70% identical to its human homologue) where it
makes important contacts with another ATP-directed inhibi-
tor, emodin, in the crystal structure of a complex between
emodin and CK2K [12]. This prompted us to check whether
the replacement of Val66 by alanine would result in a mutant
whose catalytic activity is comparable to wild type [39,49] but
in which inhibition by either TBB or emodin is impaired. As
shown in Fig. 2A, this is indeed the case since the IC50 of TBB
for the mutant V66A is about one order of magnitude higher
than that found with wild type CK2. The same mutation is
even more detrimental as far as inhibition by emodin is con-
cerned (Fig. 2B). It should be noted that the Km value for
ATP is not signi¢cantly a¡ected by the Val66CAla mutation.
It has to be concluded, therefore, that Val66 plays a relevant
role in the binding of diverse classes of inhibitors by CK2.
The same mutant is also less sensitive than wild type to GTP
vs radiolabeled ATP competition (IC50 values 0.35 vs 2.3 mM
in the presence of 100 WM ATP). This corroborates the ob-
servation that the Val66 to Ala mutation speci¢cally decreases
the a⁄nity of CK2 for GTP [49].
4. Discussion
In the light of the data presented it appears that TBB is by
far the most selective inhibitor of CK2 among those analyzed,
and one of the most speci¢c protein kinase inhibitors de-
scribed so far. Besides CK2 only three protein kinases out
of 33 tested display signi¢cant inhibition by TBB; their IC50
values, moreover, are one^two orders of magnitude higher
than that calculated with CK2: two of these, CDK2 and
GSK3L, are kinases belonging to the same protein kinase
subfamily (the CMGC group [50]), while the other, PHK,
belongs to another subfamily (the CaMK group).
It should be noted however that another CDK, CDK1,
closely related to CDK2, is quite refractory to TBB, thus
corroborating the notion that closely related protein kinases
may exhibit di¡erential sensitivity to a given inhibitor. From
these data, it appears that TBB is the ¢rst choice inhibitor of
CK2 available to date. Interestingly, in our hands, it also
discriminates very neatly between the two classes of pleiotro-
pic CKs, as its IC50 value with CK1 is almost 100-fold higher
than that for CK2. The Ki values, 0.4 WM and 47 WM with
CK2 and CK1, respectively, also re£ect this di¡erence which
is greater than that previously reported [28] for CK1 and CK2
preparations from rat liver both tested using casein as phos-
phorylatable substrate. In our experiments, speci¢c peptide
substrates were used that discriminate between CK1 and
CK2 [43] and the data were con¢rmed using the recombinant
enzymes expressed in bacteria (see Table 2). We have also
shown that a third class of CK, localized to the Golgi appa-
ratus (G-CK) [51] is fully refractory to TBB. The same applies
to the protein kinase piD261, also tested on casein [40], which
is required for the normal growth of yeast cells [52], but is also
detectable in higher eukaryotes. It can therefore be concluded
that the only known CK activity strongly inhibited by TBB is
that due to CK2.
TBB is not only very selective, it also is fairly e¡ective, with
an IC50 value in the low micromolar range. This property in
conjunction with cell permeability and lack of evident short
term cytotoxicity, make it useful for in vivo experiments, as
shown by its inhibition of CK2 in intact platelets [45] and its
inhibition of the phosphorylation of a CK2 protein substrate
in cultured Jurkat cells (see Fig. 1). This ¢nding corroborates
the conclusions of a recent study showing that TBB induces in
cultured tobacco cells a number of biological e¡ects which are
attributed by the authors to CK2 inhibition [53].
Both the selectivity and e⁄ciency of TBB may be improved
further by molecular modi¢cations aimed at rendering its
binding to CK2 tighter and more speci¢c. In this respect
TBB could become a promising lead for designing new com-
pounds possibly with therapeutical potential, considering that
a role for CK2 is implicated in infectious and neoplastic dis-
eases. Toward this aim the solution of the crystal structure of
CK2 complexed with TBB and a parallel mutational study of
the residues implicated in TBB interactions will be very help-
ful. Right now, valuable information was provided by the
¢nding that a CK2 mutant in which a hydrophobic residue
Fig. 2. CK2 susceptibility to inhibition by TBB (A) and emodin (B)
is reduced by Val66CAla mutation. The activity of wild type
(squares) and of V66A mutated (triangles) rCK2K subunit was as-
sayed as described under Section 2. The values represent a mean ob-
tained from at least three independent experiments with S.D. not
exceeding 14%.
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that makes contacts with the related inhibitor emodin when
the latter is bound to maize CK2K [12] has been replaced by
alanine displays reduced susceptibility to inhibition by both
emodin and TBB (see Fig. 2). This ¢nding highlights the rele-
vance of this hydrophobic residue, which is conserved in CK2
from di¡erent species, but otherwise replaced by alanine in
other protein kinases, in conferring speci¢city to TBB inhibi-
tion: it also paves the way towards the generation of CK2
mutants refractory to TBB inhibition, which may be useful for
validating the speci¢city of TBB as an inhibitor of CK2 in
vivo.
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